Daprodustat: A potential game-changer in renal anemia therapy—A perspective

The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD’s efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD a...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Muhammad Usman, Furqan, Muhammad, Mehmood, Qasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449327/
https://www.ncbi.nlm.nih.gov/pubmed/37637409
http://dx.doi.org/10.3389/fphar.2023.1249492
Descripción
Sumario:The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD’s efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials.

Ejemplares similares